Patrick H. Maxwell

Patrick H. Maxwell

Auto-generated profile, based on publicly available information

Patrick H. Maxwell

Department of Biological Sciences, Rensselaer Polytechnic Institute, Troy, USA

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 May 1999 in Nature
Verified
Journal Article
Closed access
PDF file
PMPatrick H. Maxwell
Patrick H. Maxwell
MWMichael S. Wiesener
Michael S. Wiesener
GCGin-Wen Chang
Gin-Wen Chang
SCSteven C. Clifford
Steven C. Clifford
EVEmma C. Vaux
Emma C. Vaux
PRPeter J. Ratcliffe
Peter J. Ratcliffe

30 July 1998 in Nature
Verified
Journal Article
Closed access
PDF file
PCPeter Carmeliet
Peter Carmeliet
YDYuval Dor
Yuval Dor
JHJean-Marc Herbert
Jean-Marc Herbert
DFDai Fukumura
Dai Fukumura
KBKoen Brusselmans
Koen Brusselmans
EKEli Keshet
Eli Keshet

1 August 2000 in The American Journal of Pathology
Verified
Journal Article
Closed access
KTKatherine L. Talks
Katherine L. Talks
HTHelen Turley
Helen Turley
KGKevin C. Gatter
Kevin C. Gatter
PMPatrick H. Maxwell
Patrick H. Maxwell
CPChristopher W. Pugh
Christopher W. Pugh
DFDavid Favara
David Favara

1 August 2000 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
MCMatthew E. Cockman
Matthew E. Cockman
NMNorma Masson
Norma Masson
DMDavid R. Mole
David R. Mole
PJPanu Jaakkola
Panu Jaakkola
GCGin-Wen Chang
Gin-Wen Chang
PMPatrick H. Maxwell
Patrick H. Maxwell
The von Hippel-Lindau tumor suppressor protein (pVHL) has emerged as a key factor in cellular responses to oxygen availability, being required for the oxygen-dependent proteolysis of α subunits of hypoxia inducible factor-1 (HIF). Mutations in VHL cause a hereditary cancer syndrome associated with dysregulated angiogenesis, and up-regulation of hypoxia inducible genes. Here we investigate the mechanisms underlying these processes and show that extracts from VHL-deficient renal carcinoma cells have a defect in HIF-α ubiquitylation activity which is complemented by exogenous pVHL. This defect was specific for HIF-α among a range of substrates tested. Furthermore, HIF-α subunits were the only pVHL-associated proteasomal substrates identified by comparison of metabolically labeled anti-pVHL immunoprecipitates from proteosomally inhibited cells and normal cells. Analysis of pVHL/HIF-α interactions defined short sequences of conserved residues within the internal transactivation domains of HIF-α molecules sufficient for recognition by pVHL. In contrast, while full-length pVHL and the p19 variant interact with HIF-α, the association was abrogated by further N-terminal and C-terminal truncations. The interaction was also disrupted by tumor-associated mutations in the β-domain of pVHL and loss of interaction was associated with defective HIF-α ubiquitylation and regulation, defining a mechanism by which these mutations generate a constitutively hypoxic pattern of gene expression promoting angiogenesis. The findings indicate that pVHL regulates HIF-α proteolysis by acting as the recognition component of a ubiquitin ligase complex, and support a model in which its β domain interacts with short recognition sequences in HIF-α subunits.

1 July 2005 in Molecular and Cellular Biology
Verified
Journal Article
Closed access
RRRaju R. Raval
Raju R. Raval
KLKah Weng Lau
Kah Weng Lau
MTMaxine G. B. Tran
Maxine G. B. Tran
HSHeidi M. Sowter
Heidi M. Sowter
SMStefano J. Mandriota
Stefano J. Mandriota
PRPeter J. Ratcliffe
Peter J. Ratcliffe
Defective function of the von Hippel-Lindau (VHL) tumor suppressor ablates proteolytic regulation of hypoxia-inducible factor α subunits (HIF-1α and HIF-2α), leading to constitutive activation of h...

22 July 1997 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
PMP. H. Maxwell
P. H. Maxwell
GDG. U. Dachs
G. U. Dachs
JGJonathan Gleadle
Jonathan Gleadle
LNL. G. Nicholls
L. G. Nicholls
DFDavid Favara
David Favara
PRP. J. Ratcliffe
P. J. Ratcliffe
Recent studies of tissue culture cells have defined a widespread system of oxygen-regulated gene expression based on the activation of a heterodimeric transcription factor termed hypoxia-inducible factor-1 (HIF-1). To determine whether the HIF-1 transcriptional response is activated within solid tumors and to define the consequences, we have studied tumor xenografts of a set of hepatoma (Hepa-1) cells that are wild type (wt), deficient (c4), and revertant (Rc4) for an obligatory component of the HIF-1 heterodimer, HIF-1β. Because HIF-1β is also essential for the xenobiotic response (in which it is termed the aryl hydrocarbon receptor nuclear translocator), we also studied c31 cells, which have a different defect in the xenobiotic response and form the HIF-1 complex normally. Two genes that show different degrees of HIF-1-dependent hypoxia-inducible expression in cell culture were selected for analysis—the glucose transporter, GLUT3, and vascular endothelial growth factor (VEGF). In situ hybridization showed intense focal induction of gene expression in tumors derived from wt, Rc4, and c31 cells, which was reduced (VEGF) or not seen (GLUT3) in those derived from c4 cells. In association with these changes, tumors of c4 cells had reduced vascularity and grew more slowly. These findings show that HIF-1 activation occurs in hypoxic regions of tumors and demonstrate a major influence on gene expression, tumor angiogenesis, and growth.